{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:07:18Z","timestamp":1789222038313,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008440","name":"International Parkinson and Movement Disorder Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clinthera.2026.05.005","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:24:01Z","timestamp":1780118641000},"page":"1024-1029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Use of Tiapride and Tetrabenazine in Huntington\u2019s Disease: A 25-Year Retrospective Single-Center Analysis"],"prefix":"10.1016","volume":"48","author":[{"given":"Katar\u00edna","family":"Schwarzov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9109-6205","authenticated-orcid":false,"given":"Samuel","family":"Labrecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Hemicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Horlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clancy","family":"Cerejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Peball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atbin","family":"Djamshidian-Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Seppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6749-3044","authenticated-orcid":false,"given":"Beatrice","family":"Heim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.05.005_bib0001","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0002","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington\u2019s disease: a clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0003","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.25075","article-title":"The incidence and prevalence of Huntington\u2019s disease: a systematic review and meta-analysis","volume":"27","author":"Pringsheim","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s42466-023-00285-1","article-title":"Symptomatic treatment options for Huntington\u2019s disease (guidelines of the German Neurological Society)","volume":"5","author":"Saft","year":"2023","journal-title":"Neurol Res Pract"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0014-2999(84)90563-6","article-title":"Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrine","volume":"102","author":"Pettibone","year":"1984","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0006","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0007","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","article-title":"Long-term effects of tetrabenazine in hyperkinetic movement disorders","volume":"48","author":"Jankovic","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0008","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1212\/WNL.38.3.391","article-title":"Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias","volume":"38","author":"Jankovic","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0009","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2377-9-62","article-title":"Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group\/TETRA-HD Investigators","volume":"9","author":"Frank","year":"2009","journal-title":"BMC Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2026.05.005_bib0010","doi-asserted-by":"crossref","first-page":"29s","DOI":"10.1016\/S0924-9338(00)00526-5","article-title":"The preclinical pharmacologic profile of tiapride","volume":"16","author":"Scatton","year":"2001","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0011","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1185\/03007998409109601","article-title":"Tiapride versus placebo: a double-blind comparative study in the management of Huntington\u2019s chorea","volume":"9","author":"Deroover","year":"1984","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0012","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/jpm12040589","article-title":"The many faces of Huntington\u2019s chorea treatment: the impact of sudden withdrawal of tiapride after 40 years of use and a systematic review","volume":"12","author":"Feleus","year":"2022","journal-title":"J Pers Med"},{"issue":"S4","key":"10.1016\/j.clinthera.2026.05.005_bib0013","doi-asserted-by":"crossref","first-page":"415s","DOI":"10.1016\/0924-9338(96)89360-6","article-title":"Seventeen months of post-marketing surveillance (PMS) on tiapride on 6792 patients","volume":"11","author":"Gallhofer","year":"1996","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0014","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14656566.2024.2445728","article-title":"Valbenazine for the treatment of chorea associated with Huntington\u2019s disease","volume":"26","author":"Patino","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.36469\/9779","article-title":"Retrospective analysis of healthcare resource use, treatment patterns, and treatment-related events in patients with Huntington\u2019s disease\u2013associated chorea initiated on tetrabenazine","volume":"6","author":"Sung","year":"2018","journal-title":"J Health Econ Outcomes Res"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0016","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajmg.b.31232","article-title":"Indexing disease progression at study entry with individuals at-risk for Huntington disease","volume":"156B","author":"Zhang","year":"2011","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0017","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1038\/s41598-022-11071-5","article-title":"Associations, overlaps and dissociations between apathy and fatigue","volume":"12","author":"Daumas","year":"2022","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2026.05.005_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852915000838","article-title":"The clinical challenges of akathisia","volume":"20","author":"Lohr","year":"2015","journal-title":"CNS Spectr"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0019","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0010-440X(75)90019-X","article-title":"The many faces of akathisia","volume":"16","author":"Van Putten","year":"1975","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0020","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3389\/fneur.2019.00710","article-title":"International guidelines for the treatment of Huntington\u2019s disease","volume":"10","author":"Bachoud-L\u00e9vi","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0021","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.WNF.0000228369.25593.35","article-title":"Is history of depression a contraindication to treatment with tetrabenazine?","volume":"29","author":"Kenney","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0022","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3233\/JHD-130071","article-title":"Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study","volume":"2","author":"Dorsey","year":"2013","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.clinthera.2026.05.005_bib0023","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1212\/WNL.0000000000005817","article-title":"Evaluating depression and suicidality in tetrabenazine users with Huntington disease","volume":"91","author":"Schultz","year":"2018","journal-title":"Neurology"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T13:32:33Z","timestamp":1789219953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826001517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0149291826001517"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.05.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Use of Tiapride and Tetrabenazine in Huntington\u2019s Disease: A 25-Year Retrospective Single-Center Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}